MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA: INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMA

H. Blommestein; Uyl-de Groot CA; P. Sonneveld; S. de Groot; S. Zweegman; M.G. Franken; C. van Beurden-Tan; N. Blijlevens

doi:10.1016/j.jval.2018.09.061

MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA: INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMA

H. Blommestein, Uyl-de Groot CA, P. Sonneveld, S. de Groot, S. Zweegman, M.G. Franken, C. van Beurden-Tan, N. Blijlevens

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	S10-S11
Journal	Value in Health
Volume	21
DOIs	https://doi.org/10.1016/j.jval.2018.09.061
Publication status	Published - 24 Dec 2018

Access to Document

10.1016/j.jval.2018.09.061

http://www.mendeley.com/research/mo1-combining-internally-valid-trial-evidence-generalizable-realworld-data-insights-effects-costs-co

Cite this

Blommestein, H., Groot CA, U., Sonneveld, P., de Groot, S., Zweegman, S., Franken, M. G., van Beurden-Tan, C., & Blijlevens, N. (2018). MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA: INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMA. Value in Health, 21, S10-S11. https://doi.org/10.1016/j.jval.2018.09.061

@article{8b7bff2251484e7db951ff14002b5864,

title = "MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA: INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMA",

author = "H. Blommestein and {Groot CA}, Uyl-de and P. Sonneveld and {de Groot}, S. and S. Zweegman and M.G. Franken and {van Beurden-Tan}, C. and N. Blijlevens",

year = "2018",

month = dec,

day = "24",

doi = "10.1016/j.jval.2018.09.061",

language = "English",

volume = "21",

pages = "S10--S11",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier Limited",

}

Blommestein, H, Groot CA, U, Sonneveld, P, de Groot, S, Zweegman, S, Franken, MG, van Beurden-Tan, C & Blijlevens, N 2018, 'MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA: INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMA', Value in Health, vol. 21, pp. S10-S11. https://doi.org/10.1016/j.jval.2018.09.061

MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA: INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMA. / Blommestein, H.; Groot CA, Uyl-de; Sonneveld, P. et al.

In: Value in Health, Vol. 21, 24.12.2018, p. S10-S11.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA: INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMA

AU - Blommestein, H.

AU - Groot CA, Uyl-de

AU - Sonneveld, P.

AU - de Groot, S.

AU - Zweegman, S.

AU - Franken, M.G.

AU - van Beurden-Tan, C.

AU - Blijlevens, N.

PY - 2018/12/24

Y1 - 2018/12/24

U2 - 10.1016/j.jval.2018.09.061

DO - 10.1016/j.jval.2018.09.061

M3 - Article

SN - 1098-3015

VL - 21

SP - S10-S11

JO - Value in Health

JF - Value in Health

ER -